Naidu Bobbili Tarun Kesava, Santosh Raju Kakarlapudi, BhaskaraRao Janapareddi V, Sunil Kumar Nallapati
General Medicine, Maharajah's Institute of Medical Sciences (MIMS), Vizianagaram, IND.
Neurology, Gitam Institute of Medical Sciences and Research, Visakhapatnam, IND.
Cureus. 2023 Jun 27;15(6):e41060. doi: 10.7759/cureus.41060. eCollection 2023 Jun.
Introduction The metabolic syndrome consists of metabolic abnormalities that increase the risk of cardiovascular disease (CVD) and cerebrovascular disease. Metabolic syndrome (MetS) is a growing problem worldwide, and substantial efforts have been made in the last years to identify early, minimally invasive blood-based biomarkers for its diagnosis. This study attempted to assess how serum Gamma-Glutamyl Transferase (GGT) performed as an ideal endogenous substance for the diagnosis of metabolic syndrome and hence estimate cardiovascular risks. Methodology This study has been undertaken to assess the role of GGT as a marker in the diagnosis of metabolic syndrome and to assess the sensitivity and specificity of GGT in the diagnosis of metabolic syndrome. One hundred and eighty subjects were recruited comprising 90 cases of MetS and an equal number of age and gender-matched controls. Patients were recruited into the study group after satisfying the International Diabetes Federation (IDF) criteria for MetS. GGT values were obtained for both groups apart from other parameters. The patients in the study were also evaluated for the presence of cardiovascular diseases and cerebrovascular accidents (CVA). Results Sixty cases have GGT levels above the normal range (55 in males and 38 in females), and none in the control group have GGT levels above normal. This difference is statistically significant (=0.01). The sensitivity was found to be 67% and 94% for males and females respectively. The specificity was found to be 100% and 98% for males and females respectively. Among the 90 cases, 20 (22.2%) patients developed cardiovascular disease. None in the control group developed cardiovascular disease. This difference is statistically significant (<0.05). Conclusion Serum GGT appears to be an easily available and fairly good marker for diagnosing patients with metabolic syndrome and is independent of other parameters of metabolic syndrome. It is also a strong predictor of cardiovascular disease. Hence GGT can be considered a potential marker for the evaluation of patients with metabolic syndrome.
引言 代谢综合征由多种代谢异常组成，这些异常会增加心血管疾病（CVD）和脑血管疾病的风险。代谢综合征（MetS）在全球范围内是一个日益严重的问题，过去几年人们付出了巨大努力来寻找早期、微创的基于血液的生物标志物用于其诊断。本研究试图评估血清γ-谷氨酰转移酶（GGT）作为诊断代谢综合征的理想内源性物质的表现，并由此估计心血管风险。
方法 本研究旨在评估GGT作为代谢综合征诊断标志物的作用，并评估GGT在代谢综合征诊断中的敏感性和特异性。招募了180名受试者，包括90例代谢综合征患者以及数量相等的年龄和性别匹配的对照组。患者在满足国际糖尿病联盟（IDF）代谢综合征标准后被纳入研究组。除其他参数外，还获取了两组的GGT值。研究中的患者还接受了心血管疾病和脑血管意外（CVA）的评估。
结果 60例患者的GGT水平高于正常范围（男性55例，女性38例），对照组中无一例GGT水平高于正常。这种差异具有统计学意义（=0.01）。男性和女性的敏感性分别为67%和94%。男性和女性的特异性分别为100%和98%。在90例患者中，20例（22.2%）发生了心血管疾病。对照组中无一例发生心血管疾病。这种差异具有统计学意义（<0.05）。
结论 血清GGT似乎是诊断代谢综合征患者的一种易于获得且相当不错的标志物，并且独立于代谢综合征的其他参数。它也是心血管疾病的有力预测指标。因此，GGT可被视为评估代谢综合征患者的潜在标志物。
